Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
iphone getting posts deleted quicker than anyone can reply!
iPhone - it is clear from the progress the company has made over the last year with the products they have developed, obtained clearance for & brought to market, things do not stand still between RNS.
I think you need to re-read the RNS history or my last posts a few times & understand the extensive operations the company are involved in - each of which could lead to a company changing RNS.
Thank you alinz. No sane person would disagree with your investment paradigm. It is what most of us set out to achieve. However, you may benefit from consulting some of Warren Buffet's investment principles. My research of the fundamentals pertaining to each company is sound in all of my investments. Consequently, I hold until I achieve my investment target in each case. This principle has worked in all but one of my investments to date. Regards.
TLWilliams - No idea why you would be surprised, although you do say the same thing over on SNG, take a look at the SP and persistent selling over recent months. You might be happy to hold shares long enough to pass them on in your will, but most people invest to make money in the shortest time possible. In my view, that's not investing, it's donating.
Yep this will come good, just needs a bit of diamond hands and patience
I am surprised at some of the negativity contributed to this board. If you truly believe what you are stating, why not sell up and move on to what you perceive to be greener pastures? Should you not be invested here, as I suspect may be the case, then why not stop wasting your time, and the time of actual IQAI investors who use this board?
Thank you readicant for outlining the IQAI investment case, and Bertie Basset for your sensible suggestion, which I hope that the negative contributors on this board may choose to follow. Regards.
a dead dog? definitely not ...
maybe you need to do a tad research in the company before you make such comments!
-- BB --
& we don't know what other developments will come from any of their many collaborations like Keck or Mayo clinic.
Too much going on here for it not to come good so its a matter of when not if + could happen at any time. Anyone of its products have the potential to transform the company.
LSN – Interest continues to increase in the recent FDA-cleared and CE-marked LSN (Liver Surface Nodularity) - marketed Q1 - A single liver biopsy can cost between $2,000 and $3,000 per test and is associated with a risk of bleeding. Biopsy sampling is also prone to errors which may result in misdiagnosis. LSN's proprietary algorithms process CT images of a patient's liver to assess the nodules along the liver surface. This low cost, low-risk, non-invasive procedure provides physicians with new information that may aid in the staging of CLD and has the potential to become the standard of care for a significant global market.
Gad Free – currently being tested – TB said only word to describe initial results was ‘wow’ in RNS – what price would you put on this tech of being world first to eliminate use of Gad - the patent application submitted in Q4 2018, is advancing through the US Patent and Trademark Office review process.
IB Trax - an entirely new platform initially targeted to assist the assessment of metastatic brain tumours, is being developed in partnership with the Mayo Clinic.
IB portfolio – with flagship Neuro imaging recognised as the national standard for use on brain tumours (recently bought by Keck & Montgomary) – Now includes recent release of IB Stroke - current annual stroke related costs are $46 billion and are projected to increase to $94 billion by 2035. By capitalizing on existing software capabilities and regulatory clearances of the IB Clinic® software suite, IB Stroke is available in both Europe (CE Marked) and the US (FDA-cleared) markets. IQ-AI intends to serve this sizable market through annual subscriptions to IB Stroke.
Auto-segmentation - will fully automate the Company's "fractional tumour burden" ("FTB") mapping process. Eliminating this manual step will also enable FTBs to be offered via IB Clinic and render the full complement of IB software as a platform independent quantitative imaging solution.
GaM trials to start July (funded by TB IF required) - "The discovery that GaM has anticancer activity against glioblastoma in an animal brain tumour model is extremely exciting; it opens the door for developing it as a drug for treatment of glioblastoma in patients", said Dr. Chitambar. "The anticancer mechanism of GaM applies to other solid tumours as well", Dr. Chitambar added.
Stonechecker – improved version released & distributors sought as interest shown in Asia
IB CAD – recent $3M grant being used to accelerate the development of this product - will have the potential to detect and identify sites of infiltrating tumor growth not visible with current imaging methods. IB CAD has the potential to detect tumor cells in non-contrast enhancing regions, thus providing the ultimate in early detection, a key advancement for cancer treatment. This technology has the potential to disrupt the way surgery is performed, how radiation treatments are planned, and how treatment therapy is assessed.
Some bought at 22p!!
And then others were suckered in by the rampers who operate here.
I ask anyone with half a brain cell this. Prior to the last RNS how did we manage to go up on no news?? Simple answer is TB or someone in the know stopped selling, which increased the SP by 2p to allow the buffer to take the hit which was coming with the RNS, if the selling tap wasn’t turned off this was heading for sub 5p.
Absolute joke. Bought in on the hype at 18p and nothing but retrace in sp since. Disgusted.
what a weasel.......only got to look at his other ventures to see how it works!
Is 5p incoming? What an absolute **** show this stock is. Constantly being dumped for 7 months. No sign of buyers stepping in.
My own opinion is takeover on the cards but ONLY once the SP has been dragged down to pitiful levels. This is TB you’re dealing with.... need I say more?
Normal service has resumed.
Trevor might just have his hand on the TO button :-)
He has filled his treasure trove ....
TB Forgot to press the sell button today. Normal service will resume tomorrow.
we need to celebrate days like this ... even it's up just 0.33%!!
-- BB --